Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Dimple A. Modi · SciRah

Researcher profile · Semantic Scholar

Dimple A. Modi

Share profile

Dimple A. Modi — researcher profile on SciRah

h-index: 12
Works: 26
Citations: 506

Most-cited papers

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors
S. Piha-Paul, J. Sachdev, M. Barve, P. LoRusso +11 more
2019Clinical Cancer Research101 citations Open access
Semantic Scholar
PTEN loss in the fallopian tube induces hyperplasia and ovarian tumor formation
A. Russo, Austin A. Czarnecki, M. Dean, Dimple A. Modi +6 more
2018Oncogene69 citations Open access
Semantic Scholar
A phase 1 study of the pan‐bromodomain and extraterminal inhibitor mivebresib (ABBV‐075) alone or in combination with venetoclax in patients with relapsed/refractory acute myeloid leukemia
G. Borthakur, O. Odenike, I. Aldoss, D. Rizzieri +7 more
2021Cancer58 citations Open access
Semantic Scholar
Mutant p53 expression in fallopian tube epithelium drives cell migration
S. Quartuccio, S. Karthikeyan, Sharon L Eddie, D. Lantvit +4 more
2015International Journal of Cancer51 citations Open access
Semantic Scholar
Targeting of follicle stimulating hormone peptide-conjugated dendrimers to ovarian cancer cells.
Dimple A. Modi, Suhair Sunoqrot, Jason Bugno, D. Lantvit +2 more
2014Nanoscale51 citations
Semantic Scholar
Insulin and insulin-like growth factor signaling increases proliferation and hyperplasia of the ovarian surface epithelium and decreases follicular integrity through upregulation of the PI3-kinase pathway
S. King, Dimple A. Modi, Sharon L Eddie, Joanna E. Burdette
2013Journal of Ovarian Research28 citations Open access
Semantic Scholar
Eftozanermin alfa (ABBV-621) monotherapy in patients with previously treated solid tumors: findings of a phase 1, first-in-human study
P. LoRusso, M. Ratain, T. Doi, D. Rasco +13 more
2022Investigational new drugs24 citations Open access
Semantic Scholar
PAX2 Function, Regulation and Targeting in Fallopian Tube-Derived High Grade Serous Ovarian Cancer
Dimple A. Modi, Rosemarie D. Tagare, S. Karthikeyan, Angela Russo +4 more
2016Oncogene24 citations Open access
Semantic Scholar
Activity of eftozanermin alfa plus venetoclax in preclinical models and patients with acute myeloid leukemia
S. Tahir, E. Calvo, B. Carneiro, J. Yuda +16 more
2023Blood16 citations Open access
Semantic Scholar
Gonadotropins Activate Oncogenic Pathways to Enhance Proliferation in Normal Mouse Ovarian Surface Epithelium
Tyvette S. Hilliard, Dimple A. Modi, Joanna E. Burdette
2013International Journal of Molecular Sciences16 citations Open access
Semantic Scholar
Reduced PAX2 expression in murine fallopian tube cells enhances estrogen receptor signaling.
J. Colina, Peter Varughese, S. Karthikeyan, A. Salvi +2 more
2019Carcinogenesis14 citations Open access
Semantic Scholar
Results from the first-in-human study of mivebresib (ABBV-075), a pan-inhibitor of bromodomain and extra terminal proteins, in patients with relapsed/refractory acute myeloid leukemia.
O. Odenike, J. Wolff, G. Borthakur, I. Aldoss +8 more
2019Journal of Clinical Oncology12 citations
Semantic Scholar
First-in-Human Study of Abbv-621, a TRAIL Receptor Agonist Fusion Protein, in Patients (Pts) with Relapsed/Refractory (RR) Acute Myeloid Leukemia (AML) and Diffuse Large B-Cell Lymphoma (DLBCL)
M. D. de Jonge, B. Carneiro, Lot L. Devriese, T. Doi +8 more
2019Blood10 citations
Semantic Scholar
Co-clinical Modeling of the Activity of the BET Inhibitor Mivebresib (ABBV-075) in AML
D. Albert, N. Goodwin, A. Davies, J. Rowe +20 more
2022In Vivo8 citations Open access
Semantic Scholar
Two Phase 1b Studies Evaluating the Safety and Tolerability of BET Inhibitors, ABBV-744 and Mivebresib, as Monotherapies and in Combination with Ruxolitinib or Navitoclax in Patients with Myelofibrosis
J. Mascarenhas, R. Saab, Deanna Brackman, Dimple A. Modi +3 more
20207 citations Open access
Semantic Scholar
Molecular response cutoffs and ctDNA collection timepoints influence on interpretation of associations between early changes in ctDNA and overall survival in patients treated with anti-PD(L)1 and/or chemotherapy
H. Andrews, Névine Zariffa, Katherine K. Nishimura, Yu Deng +16 more
2025Journal for ImmunoTherapy of Cancer5 citations Open access
Semantic Scholar
Ex Vivo Drug Sensitivity and Functional Genomics Platform Identifies Novel Combinations Targeting Intrinsic and Extrinsic Apoptotic Signaling Pathways in Multiple Myeloma
Ariosto S. Siqueira Silva, Rafael Renatino-Canevarolo, M. Meads, Maria D. Coelho Siqueira Silva +15 more
20204 citations
Semantic Scholar
A phase 1 study of REGN6569, a GITR mAb, in combination with cemiplimab in patients (pts) with advanced solid tumor malignancies: Initial dose-escalation results.
N. Lakhani, Omid Hamid, I. Braña, M. J. Lostes-Bardaji +15 more
2024Journal of Clinical Oncology2 citations Open access
Semantic Scholar
AML-058: First-In-Human Study of a Trail Receptor Agonist Fusion Protein, Eftozanermin Alfa, in Patients with Relapsed/Refractory Acute Myeloid Leukemia and Diffuse Large B-Cell Lymphoma
M. Jongen-Lavrencic, J. Yuda, R. Mous, A. Olszewski +10 more
20202 citations
Semantic Scholar
Biomarker Modulation By Mivebresib (ABBV-075) +/- Venetoclax in Relapsed/Refractory Acute Myeloid Leukemia
G. Borthakur, O. Odenike, I. Aldoss, D. Rizzieri +7 more
2019Blood2 citations Open access
Semantic Scholar
Gene expression and cytokine modulation in a first in human (FIH) study of a pan BET inhibitor ABBV-075 in solid tumors.
B. O'Neil, Dimple A. Modi, P. LoRusso, S. Wong +10 more
20182 citations
Semantic Scholar
35 The impact of treatment modalities on use of ctDNA as an early endpoint in aNSCLC trials
H. Andrews, Névine Zariffa, K. Nishimura, Emily M. Goren +17 more
2024Regular and Young Investigator Award Abstracts1 citations Open access
Semantic Scholar
LBA-01. Tumor and systemic molecular / immune correlates and patient reported QOL in pediatric CNS and solid tumors treated with PD1 inhibition and conventional versus hypofractionated radiation on PNOC013
Cassie Kline, J. Schoenfeld, Dimple A. Modi, N. Fiaschi +39 more
2025Neuro-Oncology Pediatrics0 citations Open access
Semantic Scholar
Pharmacodynamic effects in blood and tumor tissue of eftozanermin alfa, a tumor necrosis factor-related apoptosis-inducing ligand receptor agonist.
M. Motwani, Dimple A. Modi, S. Penugonda, Chun Zhang +5 more
20200 citations
Semantic Scholar
PF254 RESULTS FROM THE FIRST-IN-HUMAN STUDY OF MIVEBRESIB (ABBV-075), A PAN-INHIBITOR OF BROMODOMAIN AND EXTRA TERMINAL PROTEINS, IN PATIENTS WITH RELAPSED/REFRACTORY ACUTE MYELOID LEUKEMIA
G. Borthakur, O. Odenike, J. Wolff, I. Aldoss +8 more
2019HemaSphere0 citations Open access
Semantic Scholar
Modeling Precursor Lesions by Targeting Key Molecular Pathways in High-Grade Serous Ovarian Cancer
Dimple A. Modi
20160 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

M. Motwani×8
Invite
M. Motwani — researcher profile on SciRah
J. Wolff×6
Invite
J. Wolff — researcher profile on SciRah
Beibei Hu×5
Invite
Beibei Hu — researcher profile on SciRah
Joanna E. Burdette×5
Invite
Joanna E. Burdette — researcher profile on SciRah

×5

Invite

G. Borthakur — researcher profile on SciRah

Invite

O. Odenike — researcher profile on SciRah

Invite

I. Aldoss — researcher profile on SciRah

Invite

D. Rizzieri — researcher profile on SciRah

Invite

T. Prebet — researcher profile on SciRah

Invite

B. Jonas — researcher profile on SciRah

Invite

E. Calvo — researcher profile on SciRah

Invite

P. LoRusso — researcher profile on SciRah